That is a great question, I think it is dependent on a number of variables.
- Hype – often this is dictated by investors and popularity.
- Forecasted growth – This will grow in the next 12 months
- Maturity / potential of the company – This will grow in the next 12 months
I do believe that ALC has a significant re-rate in store. However, there needs to be a realisation from new investors of who/what we do at the end of the day.
A realisation is also needed on the whole Health IT sector imo.
price to sales ratio, page-2
Add ALC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
-0.003(4.84%) |
Mkt cap ! $79.20M | |||
| Open | High | Low | Value | Volume |
| 6.2¢ | 6.2¢ | 5.9¢ | $23.77K | 397.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 509364 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 631910 | 3 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.9¢ |
Change
-0.003 ( 6.35 %) |
||||
| Open | High | Low | Volume | ||
| 6.1¢ | 6.1¢ | 5.9¢ | 223472 | ||
| Last updated 15.21pm 17/05/2024 ? | |||||
| ALC (ASX) Chart |